Andrew Asa Hindman
Net Worth
Last updated:
What is Andrew Asa Hindman net worth?
The estimated net worth of Mr. Andrew Asa Hindman is at least $8,696,085 as of 18 Nov 2022. He owns shares worth $5,511,420 as insider, has earned $716,235 from insider trading and has received compensation worth at least $2,468,430 in Theravance Biopharma, Inc..
What is the salary of Andrew Asa Hindman?
Mr. Andrew Asa Hindman salary is $822,810 per year as Senior Vice President & Chief Financial Officer in Theravance Biopharma, Inc..
How old is Andrew Asa Hindman?
Mr. Andrew Asa Hindman is 52 years old, born in 1973.
What stocks does Andrew Asa Hindman currently own?
As insider, Mr. Andrew Asa Hindman owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | Senior Vice President & Chief Financial Officer | 409,771 | $13.45 | $5,511,420 |
What does Theravance Biopharma, Inc. do?
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Andrew Asa Hindman insider trading
Theravance Biopharma, Inc.
Mr. Andrew Asa Hindman has made only one insider trade in 2022, according to the Form 4 filled with the SEC. He sold 65,000 units of TBPH stock worth $716,235 on 18 Nov 2022.
As of 18 Nov 2022 he still owns at least 409,771 units of TBPH stock.
Theravance Biopharma key executives
Theravance Biopharma, Inc. executives and other stock owners filed with the SEC:
- Mr. Andrew Asa Hindman (52) Senior Vice President & Chief Financial Officer
- Mr. Rick E. Winningham M.B.A. (65) Chairman & Chief Executive Officer